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ABSTRACT
Background Uveal melanoma (UM) is the most
common primary cancer of the eye in adults. About half
of the patients are at risk of developing metastatic
disease resulting in a poor clinical prognosis. Metastatic
progression is strongly associated with loss of one
chromosome 3 in the tumour (monosomy 3). The
tumour suppressor gene BAP1 was found to be
recurrently mutated in UM with monosomy 3. Familial
UM is rare and amounts to about 0.6–6% of all
patients with melanoma. However, BAP1 germline
mutations have been identiﬁed in rare hereditary tumour
syndromes, including cases with UM. One may assume
that UM may be part of these hereditary conditions with
predisposition to malignant cancers.
Methods The patients underwent complete
ophthalmological workup and enucleation due to UM.
Microsatellite analysis was performed to determine the
chromosome 3 status of the tumours. Sanger sequencing
of all coding exons of the BAP1 gene was performed in
blood DNA of the patients.
Results Here we report on two family members
(mother and son) diagnosed with UM. In both patients,
a cosegregating BAP1 germline mutation (c.299 T>C)
was found. The mutant BAP1 allele was retained in the
tumour of the son showing monosomy 3. The son
further developed urothelial carcinoma and liver
metastasis, the mother was affected by the UM and
cholangiocellular carcinoma.
Conculsions We detected a cosegregating BAP1
germline mutation in two family members with UM. This
suggests that, consistent with a classic tumour
suppressor model, carriers of damaging mutations in
BAP1 are predisposed to UM. However, as BAP1
germline mutations have been found to cause other
cancer syndromes as well, there must be other factors
that decide about the type of tumour emerging from
BAP1 inactivation.
INTRODUCTION
Uveal melanoma (UM) is the second most common
form of melanoma and the most common primary
cancer of the eye in adults and has a strong propen-
sity for fatal metastasis.1 The exact aetiology of this
cancer remains unclear. UM can arise anywhere in
the uveal tract including ciliary body and choroid.
Frequently, more than one of these structures are
involved. UM is usually sporadic and the average
age at diagnosis of primary tumour is in the
mid-50s. However, there are rare cases of familial
UM, comprising only ∼0.6–6% of all patients with
UM.2 3 There are 73 such cases documented in the
literature, including the family in this report.4–6
Loss of one chromosome 3 (monosomy 3) in the
tumour is strongly associated with metastatic death
of patients suggesting that inactivating mutations of
a gene on the remaining chromosome 3 promotes
metastasis.7
BAP1, which maps to 3p21, codes for an ubiqui-
tin carboxy-terminal hydrolase that interacts with
the Really Interesting New Gene (RING) ﬁnger
domain of the breast cancer 1 early onset protein
(BRCA1).8 9 This gene is thought to be a tumour
suppressor gene that functions in the BRCA1
growth control pathway.8 10 In BRCA1 mutation
carriers, multiple neoplasms and family history of
breast cancer occur frequently. A higher frequency
of UM in BRCA germline mutation carriers than
predicted has been reported recently.11
Lately, Harbour et al12 reported BAP1 inactivat-
ing mutations which were predominantly found in
UMs with high metastatic potential. BAP1 germline
truncating mutation predispose to a hereditary
cancer syndrome including UM, lung adenocarcin-
oma, neuroendocrine carcinoma, meningioma,
cutaneous melanoma and possibly other cancers.13
Additionally, Wiesner et al14 described an auto-
somal dominant syndrome that is caused by germ-
line mutations of BAP1, characterised by a high
penetrance of melanocytic neoplasms possibly asso-
ciated with an increased risk for uveal and cutane-
ous melanomas. Here we report a germline BAP1
mutation cosegregating with UM in two affected
ﬁrst degree family members.
METHODS
Patients
Informed consent of the patients was obtained; the
study was in adherence to the tenets of the
Declaration of Helsinki. Mother and son under-
went complete ophthalmological workup including
slit lamp examination, funduscopy, gonioscopy,
a-scan and b-scan ultrasound, and as far as needed
ﬂuorescein angiography. The primary tumours of
both patients were treated by enucleation.
Histopathological analysis was performed.
Genetic analyses
The son’s tumour DNA was isolated from fresh
frozen tumour as described elsewhere.15 DNA from
the mother’s tumour was prepared from formalin
ﬁxed parafﬁn embedded tumour tissue using the
QIAamp DNA Mini Kit (Qiagen, Hilden,
Germany) following the protocol: ‘Isolation of
genomic DNA from parafﬁn-embedded tissue’.
Chromosome 3 typing was performed by micro-
satellite analysis using eight chromosome 3 markers
as described elsewhere.15 Sequence analysis of all
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BAP1 exons was performed on genomic DNA from blood cells
and tumour tissue. Oligonucleotide primers were designed to
amplify all 17 BAP1 exons.16 PCR was performed on 20 ng
genomic DNA using Green GoTaq DNA Polymerase (Promega,
Madison, USA) in a total volume of 25 mL following the
manufacturer’s instructions. Annealing temperature for all
primers was set to 62°C. Sanger sequencing was performed with
routine methods using the PCR primers. BAP1 mutation
(c.299T>C) refers to cDNA with accession number
NM_004656.2.
Figure 1 H&E staining of the ciliary body melanoma of the mother. (A) Mixed-cell malignant melanoma of the ciliary body and iris with
inﬁltration of the trabecular meshwork (magniﬁcation 5×). (B) The tumour is composed of tightly-packed bundles of spindle-shaped cells
(magniﬁcation 20×). (C) Slender nuclei and epitheloid cells (arrowhead) with abundant eosinophilic cytoplasm, large nuclei and prominent nucleoli
as well as a few pigmented cells (arrow) are visible (magniﬁcation 40×). Access the article online to view this ﬁgure in colour.
Figure 2 Clinical evaluation of the
son before treatment. (A) Slit lamp
examination: visible tumour in the
chamber angle at 5.30 o’clock
position. (B) Gonioscopy: tumour mass
in the chamber angle. (C) Slit lamp
examination with dilated pupil: tumour
mass visible behind the lens. (D) Slit
lamp examination in retroillumination:
intravitreal tumour mass. (E) B-scan
ultrasound: mushroom shaped
melanoma of the choroid. (F) A-scan
ultrasound: low reﬂectivity of tumour
tissue. Access the article online to view
this ﬁgure in colour.
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RESULTS
In 1997, the mother was diagnosed with UM of the ciliary body
at the age of 56 years. Since 1991 a tumour of the chamber
angle from the 6 o’clock to 10 o’clock position was controlled.
After development of secondary glaucoma with intraocular pres-
sure as high as 40 mm Hg, a biopsy of the tumour was per-
formed and an UM with involvement of the ciliary body was
diagnosed. Therefore the eye was enucleated. Histological ana-
lysis revealed an UM of mixed cellular structure which affected
the ciliary body and iris (ﬁgure 1). An inﬁltration of the trabecu-
lar meshwork could be observed. There was no evidence for
metastasis in 1998. Since then, the patient has not developed
metastasis. In February 2012 an intrahepatic cholangiocellular
carcinoma was diagnosed and treated by resection. In October,
a relapse was treated by hemihepatectomy. Since then, no other
neoplasms have developed and the patient is of good health
now.
The son was diagnosed with UM in 2007 at the age of 45
years. Initially, a tumour of the chamber angle was observed by
slit lamp examination and gonioscopy (ﬁgure 2A,B). With
dilated pupil and in retroillumination, a prominent intravitreal
tumour mass was present (ﬁgure 2C,D). B-scan ultrasonography
showed a mushroom shaped UM (ﬁgure 2E). A-scan ultrasonog-
raphy revealed low reﬂectivity (ﬁgure 2F). The maximal prom-
inence of the tumour was 6 mm to the sclera. The patient
underwent proton radiation in November 2007, followed by a
trans-scleral tumour resection in December 2007. In February
2008, May 2009 and July 2009, a recurring retinal detachment
was ﬁnally successfully treated by silicone oil tamponade.
In February 2010, an urothelial carcinoma was treated by
operation and sixfold local chemotherapy. In February 2011 a
recurrence of the ciliary body tumour was noted (ﬁgure 3) and
the eye was enucleated in March 2011. Histological analysis
revealed a nodular proliferating melanoma composed of pleo-
morphic eosinophilic cells with pleomorphic, eccentrically loca-
lised nuclei (ﬁgure 4). The patient was diagnosed with liver
metastasis in segments 5, 7 and 8 in July 2011 and was treated
by local radio frequency thermal ablation without obtaining a
biopsy.
Mother and son did not smoke or were exposed to chemicals.
Dermatological workup of the patients and family members did
not reveal cutaneous melanoma or atypical cutaneous naevi.
Genotyping of the tumour DNAs of the mother and son by
microsatellite analysis using eight chromosome 3 markers15
revealed loss of heterozygosity of all informative markers, con-
sistent with monosomy 3. Sequence analysis of all 17 exons of
the BAP1 gene in DNA from the son’s tumour revealed a mis-
sense mutation (c.299T>C) in exon 5. The same mutation was
detected at heterozygous state in the blood DNAs from the son
and the mother (ﬁgure 5) by Sanger sequencing. Other family
members did not undergo BAP1 sequencing.
There was no history of UM, breast or ovarian cancer in any
other family member, but the pedigree revealed several other
neoplasias (ﬁgure 6).
DISCUSSION
Several lines of evidence strongly suggest that BAP1 plays a
major role in tumour development. Harbour et al12 found
inactivating somatic mutations in 26 of 31 (84%) metastasising
tumours and usually BAP1 mutations are seen on the remaining
allele in tumours with monosomy 3. As the two-step mutational
inactivation of this gene complies with the classical tumour sup-
pressor gene model, it is plausible that inactivating BAP1 germ-
line mutations can be a cause of inherited predisposition to this
cancer. Familial UM is reported to be a rare condition compris-
ing only ∼0.6–6% of all patients with UM.2 3
In the present study, we report on a BAP1 germline mutation
associated with familial UM. In the tumour of the son, mono-
somy 3 was observed with the mutated BAP1 allele retained
Figure 3 Slit lamp examination of the anterior segment: visible
recurrence of the tumour in the chamber angle at the 9 o’clock
position. Access the article online to view this ﬁgure in colour.
Figure 4 H&E staining of the
melanoma of the ciliary body of the
son. (A) Uveal melanoma with nodular
growth pattern and inﬁltration of the
ciliary body (5× magniﬁcation). (B) The
uveal melanoma is composed of highly
atypical melanocytes with abundant
eosinophilic cytoplasm, eccentrically
located, pleomorphic and
hyperchromatic nuclei and prominent
nucleoli (arrow). Some tumour cells are
pigmented. A few multinucleated
tumour cells (arrowhead) and atypical
mitoses (20× magniﬁcation). Access
the article online to view this ﬁgure in
colour.
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suggesting complete inactivation of BAP1. This is in concord-
ance with an assumed tumour suppressor gene function of
BAP1. The missense mutation found in exon 5 of the BAP1
gene causes replacement of Leucine with Proline at codon 100
(L100P). We used Sorting Intolerant From Tolerant (SIFT) and
Polyhen-2 to predict whether the amino acid substitution affects
BAP1 protein function.17 18 According to both algorithms, the
change in amino acid sequence of BAP1 as found in the affected
patients is classiﬁed as damaging, with a PolyPhen-2 probability
score of 1.
Although both patients carry the same germline mutation, the
course of disease is different. Age at diagnosis of the primary UM
was 56 years for the mother and thereafter no other neoplasia
was diagnosed. With 45 years of age, the son was much younger
when diagnosed with UM. Shortly after, he has been diagnosed
with a second tumour and metastatic UM suggesting a more
severe course of disease. Previously BAP1 germline mutations
have been reported to cosegregate with other tumours such as
mesothelioma or melanocytic tumours in other families.12 13
The results of our study provide further evidence that BAP1
germline mutations predispose to tumours including UM.
However, the predominant type of tumour varies between dif-
ferent families thus the tumour entity might depend on
additional factors. More families with BAP1 germline mutation
have to be identiﬁed and investigated to determine these factors.
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Figure 5 Sanger sequencing of BAP1
exon 5 demonstrating a heterozygous
mutation (c.299 T>C, indicated by
arrows) in blood DNA from the
affected patients (mother and son).
The tumour of the son shows loss of
the normal allele. The
electropherogram shows a
heterozygous T>C substitution that
replaces Leucine by Proline at codon
100. Access the article online to view
this ﬁgure in colour.
Figure 6 Pedigree of the family with inherited uveal melanoma. Only
the patients affected by uveal melanoma (I.2, II.2) were examined at
the Department of Ophthalmology, University of Regensburg.
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